by GlobeNewsWire | Sep 12, 2016 | Globe Newswire
GAINESVILLE, Fla., and CAMBRIDGE, Mass., Sept. 12, 2016 (GLOBE NEWSWIRE) — Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of...
by GlobeNewsWire | Aug 11, 2016 | Globe Newswire
Ongoing Phase 1/2 trial DTX101 for hemophilia B clinical data expected later this year Lead IMD program, DTX301 for OTC deficiency, progressing toward IND filing Advancing broad inherited metabolic disease (IMD) portfolio with programs addressing citrullinemia type 1,...
by GlobeNewsWire | Aug 11, 2016 | Globe Newswire
VY-AADC01 Phase 1b Study for Advanced Parkinson’s Disease On Track to Report Six-Month Safety, Motor Function, and Biomarker Data from Cohorts 1 and 2 by Year-End 2016 Pipeline Advances with Selection of Lead Clinical Candidates for Multiple Pipeline Programs by Late...
by GlobeNewsWire | Aug 10, 2016 | Globe Newswire
Updated timing of the completed BLA submission for voretigene neparvovecEarlier today, released additional positive data from the pivotal Phase 3 trial of voretigene neparvovecReported positive preliminary safety and efficacy from the Phase 1/2 clinical trial of...
by GlobeNewsWire | Aug 9, 2016 | Globe Newswire
On track to enroll first patients for Phase I/II clinical trial of RGX-501 for the treatment of homozygous familial hypercholesterolemia in the second half of 2016Received FDA Rare Pediatric Disease Designation for RGX-121 for the treatment of Mucopolysaccharidosis...